Acute Heart Failure Clinical Trial
— ELUSIAOfficial title:
Evaluation of Lung UltraSound In Acute Heart Failure (ELUSIA)
Verified date | September 2019 |
Source | Cantonal Hosptal, Baselland |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Acute heart failure is a life threatening condition requiring rapid diagnosis and treatment.
However, the differentiation between heart failure and other conditions presenting with acute
dyspnea is notoriously difficult in the emergency room. Point-of-care lung ultrasound is a
simple, rapid and noninvasive technique directly visualizing fluid content in the lung as
evidence for acute heart failure. A number of publications showed the diagnostic utility of
lung ultrasound in the diagnosis of heart failure, but many open questions remain.
The goal of this study is to evaluate the diagnostic accuracy of lung ultrasound to predict a
cardiac origin of dyspnea in unselected patients in the emergency room as compared to
standard evaluation. Further goals are to evaluate if lung ultrasound provides additional
diagnostic information as compared to clinical examination, NT-proBNP and chest X-ray, to
compare the diagnostic accuracy of lung ultrasound in different patient subgroups (heart
failure with preserved vs reduced ejection fraction, de novo vs decompensated chronic heart
failure, age ≥75 vs <75 years, women vs men and presence vs absence of concomitant pulmonary
disease) and to compare demographics and clinical characteristics in different patient
populations.
300 patients, aged ≥18 years presenting to the emergency room (ER) with acute dyspnoe as
principal complaint will undergo initial clinical assessment of the likely etiology of
dyspnea by the ER physician in charge. The second assessment by the same physician will
include results of NT-proBNP according to predefined cutoffs. Final diagnosis ("Gold
Standard") will be done by two experienced investigators after patient discharge taking into
account the complete medical record except the results of lung ultrasound. Assessment of
chest X-ray and lung ultrasound by investigators will be preforemd blinded regarding all
other results.
Status | Completed |
Enrollment | 56 |
Est. completion date | September 30, 2018 |
Est. primary completion date | September 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: Emergency room presentation with acute dyspnoe as principal complaint (either new or worsening in the last 48 hours) Age =18 years. Exclusion criteria: Immediately life threatening condition (cardiac arrest, ST-elevation myocardial infarction, shock, respiratory failure requiring intubation) No consent. |
Country | Name | City | State |
---|---|---|---|
Switzerland | Cantonal Hospital Baselland | Bruderholz | BL |
Lead Sponsor | Collaborator |
---|---|
Prof. Dr. Jörg Leuppi |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Value of lung ultrasound in the diagnosis of acute heart failure | Presence/Absence of heart failure | at the time of inclusion into the study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02151383 -
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
|
Phase 2 | |
Completed |
NCT02135835 -
A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure
|
Phase 4 | |
Recruiting |
NCT05556044 -
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
|
Phase 3 | |
Recruiting |
NCT04363697 -
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
|
Phase 4 | |
Completed |
NCT02122640 -
Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department
|
N/A | |
Not yet recruiting |
NCT01211886 -
Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)
|
N/A | |
Completed |
NCT01193998 -
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
|
N/A | |
Not yet recruiting |
NCT06465498 -
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
|
N/A | |
Recruiting |
NCT05276219 -
Optimized Treatment of Pulmonary Edema or Congestion
|
Phase 4 | |
Recruiting |
NCT05392764 -
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03157219 -
Manipal Heart Failure Registry (MHFR)
|
N/A | |
Completed |
NCT06024889 -
Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.
|
Phase 1/Phase 2 | |
Terminated |
NCT04174794 -
Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
|
||
Recruiting |
NCT05972746 -
Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure
|
N/A | |
Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A | |
Completed |
NCT02141607 -
Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
|
||
Completed |
NCT01870778 -
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
|
Phase 3 | |
Recruiting |
NCT05986773 -
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
|
Phase 4 | |
Recruiting |
NCT04163588 -
Sequential Nephron Blockade in Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03720288 -
Acetazolamide in Patients With Acute Heart Failure
|
Phase 3 |